What is HIV Cholangiopathy?
HIV cholangiopathy is a biliary tract disease occurring in severely immunosuppressed AIDS patients (typically CD4+ count <100 cells/μL) characterized by opportunistic infection-related strictures and inflammation of the bile ducts, presenting with cholestatic liver injury and biliary obstruction. 1
Clinical Definition and Pathophysiology
HIV cholangiopathy represents a form of secondary sclerosing cholangitis related to infectious cholangitis in the setting of AIDS and severe immunodepression 1. This condition manifests as a syndrome of biliary obstruction and liver damage due to infection-related strictures of the biliary tract 2. The disease is highly associated with opportunistic infections, with Cryptosporidium parvum being the most common infectious etiology, though cytomegalovirus (CMV) is also frequently implicated 3.
The pathophysiology involves infection-related damage to the biliary tree, though anti-infective therapy is usually ineffective once the structural damage has occurred 4.
Clinical Presentation
Patients typically present with:
- Biliary-type abdominal pain (right upper quadrant/epigastric) - most common symptom 5, 6
- Anicteric cholestasis (jaundice may be absent despite cholestatic pattern) 4
- Chronic diarrhea and weight loss 3
- Nausea and vomiting 5
- Some patients may be asymptomatic (20% in one series) 6
Laboratory hallmarks include markedly elevated alkaline phosphatase and gamma-glutamyltransferase with mild to moderate transaminase elevations 3.
Diagnostic Features
Cholangiographic Patterns
ERCP demonstrates characteristic abnormalities, with papillary stenosis being the most common finding (77% of cases), followed by sclerosing cholangitis pattern with intrahepatic and extrahepatic bile duct strictures 6. Other patterns include:
- Distal common bile duct strictures 5
- Intrahepatic duct irregularities
- Combined patterns
Imaging Approach
Abdominal ultrasonography is abnormal in virtually all patients and serves as the first-line screening modality 3, 6. When ultrasound shows biliary abnormalities in a patient with CD4 count <100 cells/μL, ERCP is both the gold standard for diagnosis and offers therapeutic intervention 4.
Epidemiology and Risk Factors
This condition is now considered rare in the era of highly active antiretroviral therapy (HAART) and primarily occurs in settings of:
- Poor access to antiretroviral therapy
- Medication non-compliance 2
- Development of drug resistance (evidenced by precipitous CD4 drop despite therapy) 6
Important caveat: De novo cholangiopathy can develop in patients already on antiretroviral therapy, which may indicate treatment failure or resistance and portends a worse prognosis 6.
Management and Prognosis
Endoscopic sphincterotomy provides reliable and prompt resolution of abdominal pain in patients with papillary stenosis 6. Biliary stent placement may be required for complex strictures 5.
Cholangiographic abnormalities can regress with effective antiretroviral therapy, demonstrating the importance of immune reconstitution 6. However, prognosis ultimately relates to the underlying stage of AIDS 4. Median survival following diagnosis is approximately 34 months with modern therapy 6, representing improvement over historical outcomes.
Critical Clinical Pearls
- Consider HIV cholangiopathy in any HIV-positive patient with cholestatic liver profile and diarrhea, regardless of whether they are on HAART 7
- The condition carries significant mortality and requires multidisciplinary management 5
- Close follow-up for cholangiocarcinoma is required once HIV cholangiopathy is detected, as opportunistic infections can lead to malignant transformation 7
- Cryptosporidium can be identified by PCR testing of stool or biliary fluid, or acid-fast staining of stool 3